Browsing by Author rp01466

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 176 to 195 of 297 < previous   next >
TitleAuthor(s)Issue DateViews
 
PD-L1 expression in patients with anaplastic thyroid carcinoma: prevalence and outcome
Proceeding/Conference:Thyroid
Wong, KPLang, HHBLam, KOShek, TWHYau, TCC
2018
76
 
Pembrolizumab (Keytruda)
Journal:Human Vaccines & Immunotherapeutics
Kwok, GYau, TCCChiu, WYJTse, EWCKwong, YL
2016
242
 
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Journal:Liver Cancer
Kudo, MLim, HYCheng, ALChao, YYau, TCCOgasawara, SKurosaki, MMorimoto, NOhkawa, KYamashita, TLee, KHChen, ESiegel, ABRyoo, BY
2020
38
 
Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial
Journal:Journal of Clinical Oncology
Finn, RSRyoo, B-YMerle, PKudo, MBouattour, MLim, HYBreder, VEdeline, JChao, YOgasawara, SYau, TGarrido, MChan, SLKnox, JDaniele, BEbbinghaus, SWChen, ESiegel, ABZhu, AXCheng, A-LThe KEYNOTE-240 investigators
2020
95
 
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
Journal:Investigational New Drugs
Yau, TCheng, PNChan, PChan, WChen, LYuen, JPang, RFan, STPoon, RT
2012
151
 
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma
Journal:Cancer
Yau, TChan, PPang, RNg, KFan, STPoon, RT
2010
164
 
Phase 1/2 Safety and Antitumor Activity of Nivolumab in Patients With Advanced Hepatocellular Carcinoma: Interim Analysis of the CheckMate 040 Dose-Escalation Study
Proceeding/Conference:Liver Cancer
El-Khoueiry, ABSangro, BYau, TCCCrocenzi, TSWelling, TH, IIIYeo, WChopra, AAnderson, Jdela Cruz, CLang, LNeely, JMelero, I
2016
64
 
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population
Journal:Cancer
Yau, TChan, PNg, KKChok, KSHCheung, TTFan, STPoon, RT
2009
187
 
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
Journal:Clinical Cancer Research
Yau, TChen, PJChan, PCurtis, CMMurphy, PSSuttle, ABGauvin, JHodge, JPDar, MMPoon, RT
2011
135
 
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
Journal:Journal of Hepatology
Finn, RSPoon, RTPYau, TCCKlümpen, HJChen, LTKang, YKKim, TYGomez-Martin, CRodriguez-Lope, CKunz, TPaquet, TBrandt, USellami, DBruix, J
2013
59
 
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Proceeding/Conference:Journal of Clinical Oncology
Finn, RSPoon, RTPYau, TKlumpen, HChen, LKang, YKim, TGomez-Martin, CRodriguez-Lope, CKunz, TPaquet, TAsubonteng, KWinkler, REAnak, OSellami, DBBruix, J
2011
136
 
Phase I study of Pazopanib (PAZ) in Hepatocellular Carcinoma (HCC): evaluation of clinical activity, Pharmacokinetics (PK), and Dynamic Contrast Enhanced MRI (DCE-MRI)
Proceeding/Conference:European Journal of Cancer Supplements
Yau, TCCChen, PCurtis, CMurphy, PParker, GSuttle, AArumugham, THodge, JDar, MPoon, RTP
2009
75
 
A phase I study of pazopanib in patients with advanced hepatocellular carcinoma
Proceeding/Conference:Journal of Clinical Oncology
Yau, CCChen, PJCurtis, CMMurphy, PSSuttle, ABArumugham, THodge, JPDar, MMPoon, R
2009
41
 
A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma
Proceeding/Conference:Journal of Clinical Oncology
Yau, CCChan, PPang, RChan, WCheng, PNPoon, R
2010
48
 
Phase I trial of Recombinant Human Arginase 1 (PEG-BCT-100) combined with Capecitabine and Oxaliplatin (PACOX) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma
Proceeding/Conference:Symposium of Pegylated Human Recombinant Arginase in the Treatment of Cancers and other human Disease, Hong Kong
Yau, TCC
2017
42
 
A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC)
Proceeding/Conference:Journal of Hepatology
Yau, TYen, CJChen, PJChau, YLencioni, RKallender, HOttesen, LHPoon, RTP
2011
218
 
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC)
Proceeding/Conference:Journal of Clinical Oncology
Yau, TCCSukeepaisarnjaroen, WChao, YYen, CJLausoontornsiri, WChen, PJSanpajit, TLencioni, RCamp, ACCox, DSKallender, HOttesen, LHPoon, RTP
2012
88
 
Phase II open label study of single agent sorafenib in treating advanced hepatocellular carcinoma in hepatitis-B endemic Asian population: presence of lung metastasis predicts poor response
Proceeding/Conference:International Meeting Hepatocellular Carcinoma (IMHCC)
Yau, TCC
2008
13
 
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
Journal:Clinical Cancer Research
Lim, HYMerle, PWeiss, KHYau, TCCRoss, PMazzaferro, VBlanc, JFMa, YTYen, CJKocsis, JChoo, SPSukeepaisarnjaroen, WGérolami, RDufour, JFGane, EJRyoo, BYPeck-Radosavljevic, MDao, TYeo, WLamlertthon, WThongsawat, STeufel, MRoth, KReis, DChilds, BHKrissel, HLlovet, JM
2018
50
 
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
Journal:Investigational New Drugs
Yau, TWong, HChan, PYao, TJPang, RCheung, TTFan, STPoon, RT
2012
191
Showing results 176 to 195 of 297 < previous   next >